Details of the Drug

General Information of Drug (ID: DMPFN6Y)

• Drug Name: Olanzapine
• Synonyms: Lanzac; Midax; Olansek; Olanzapina; Olanzapinum; Symbyax; Zalasta; Zydis; Zyprexa; Eli Lilly brand of olanzapine; Lilly brand of olanzapine; Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis; LY 170053; ALKS-7921; KS-1090; LY-170052; LY-170053; Olanzapine (OLA); Olanzapine [USAN:INN]; Olzapin (TN); Rexapin (TN); Zalasta (TN); Zolafren (TN); Zydis (TN); Zyprexa (TN); Olanzapine (JAN/USAN/INN); 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine

Indication

Disease Entry	ICD 11	Status	REF
Bipolar depression	N.A.	Approved	[1]
Major depressive disorder	6A70.3	Approved	[1]
Schizoaffective disorder	6A21	Approved	[1]
Schizophrenia	6A20	Approved	[2]

• Therapeutic Class: Antipsychotic Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  N05AH03: Olanzapine
  N05AH: Diazepines, oxazepines, thiazepines and oxepines
  N05A: ANTIPSYCHOTICS
  N05: PSYCHOLEPTICS
  N: NERVOUS SYSTEM
  N05AH03: Olanzapine
  N05AH: Diazepines, oxazepines, thiazepines and oxepines
  N05A: ANTIPSYCHOTICS
  N05: PSYCHOLEPTICS
  N: NERVOUS SYSTEM
  N05AH03: Olanzapine
  N05AH: Diazepines, oxazepines, thiazepines and oxepines
  N05A: ANTIPSYCHOTICS
  N05: PSYCHOLEPTICS
  N: NERVOUS SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 312.4
  Logarithm of the Partition Coefficient (xlogp); 2.9
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 333 mcgh/L [3]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 150 mcg/L [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
  Bioavailability: 60% of drug becomes completely available to its intended biological destination(s) [5]
  Clearance: The clearance of drug is 29.4 L/h []
  Elimination: Olanzapine is mainly eliminated through metabolism and hence, only 7% of the eliminated drug can be found as the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 21 - 54 hours [3]
  Metabolism: The drug is metabolized via the liver [3]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.68586 micromolar/kg/day [6]
  Vd: The volume of distribution (Vd) of drug is 1000 L [3]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.01 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Drug level changed	Not Available	CYP3A4	OTQGYY83	[7]
Tardive dyskinesia	Not Available	DRD3	OT0OFFKB	[7]
Tardive dyskinesia	Not Available	DRD4	OTAJTO7N	[7]

• Chemical Identifiers:
  Formula: C17H20N4S
  IUPAC Name: 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
  Canonical SMILES: CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
  InChI: InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
  InChIKey: KVWDHTXUZHCGIO-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 135398745
  ChEBI ID: CHEBI:7735
  CAS Number: 132539-06-1
  UNII: N7U69T4SZR
  DrugBank ID: DB00334
  TTD ID: D0V4QS
  VARIDT ID: DR00462
  INTEDE ID: DR1186
  ACDINA ID: D00484
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[8]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[10]
Cytochrome P450 1A2 (CYP1A2) Main DME	DEJGDUW	CP1A2_HUMAN	Substrate	[11]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Gene/Protein Processing	[12]
5-hydroxytryptamine receptor 1A (HTR1A)	OT38K9MK	5HT1A_HUMAN	Drug Response	[13]
5-hydroxytryptamine receptor 2A (HTR2A)	OTWXJX0M	5HT2A_HUMAN	Protein Interaction/Cellular Processes	[14]
5-hydroxytryptamine receptor 2C (HTR2C)	OT6H8DE0	5HT2C_HUMAN	Drug Response	[15]
5-hydroxytryptamine receptor 6 (HTR6)	OT8GTDDY	5HT6R_HUMAN	Protein Interaction/Cellular Processes	[14]
Afamin (AFM)	OTPOR8IO	AFAM_HUMAN	Post-Translational Modifications	[16]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Post-Translational Modifications	[16]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Post-Translational Modifications	[16]
Alpha-1B-glycoprotein (A1BG)	OTFVUGNQ	A1BG_HUMAN	Post-Translational Modifications	[16]
Alpha-2-macroglobulin (A2M)	OTFTX90K	A2MG_HUMAN	Post-Translational Modifications	[16]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 06 Mental, behavioural or neurodevelopmental disorder
• Disease Class: ICD-11: 6A20 Schizophrenia
• The Studied Tissue: Pre-frontal cortex
• The Studied Disease: Schizophrenia [ICD-11:6A20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	9.39E-01	-0.01	-0.05
Dopamine D2 receptor (D2R)	DTT	DRD2	9.91E-01	-0.02	-0.28
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.19E-01	-1.32E-01	-2.77E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.65E-01	-1.47E-01	-4.48E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.73E-02	6.49E-02	3.07E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.45E-01	2.07E-02	1.74E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	2.59E-01	6.29E-02	3.14E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	4.84E-01	-8.38E-02	-8.46E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Olanzapine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Quetiapine.	Schizophrenia [6A20]	[17]
Mesoridazine	DM2ZGAN	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Mesoridazine.	Schizophrenia [6A20]	[17]
Thioridazine	DM35M8J	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Thioridazine.	Schizophrenia [6A20]	[17]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Aripiprazole.	Schizophrenia [6A20]	[17]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Iloperidone.	Schizophrenia [6A20]	[17]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Paliperidone.	Schizophrenia [6A20]	[17]
Loxapine	DM8AI9U	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Loxapine.	Schizophrenia [6A20]	[17]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Molindone.	Schizophrenia [6A20]	[17]
Chlorpromazine	DMBGZI3	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Chlorpromazine.	Schizophrenia [6A20]	[17]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Thiothixene.	Schizophrenia [6A20]	[17]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Trifluoperazine.	Schizophrenia [6A20]	[17]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Risperidone.	Schizophrenia [6A20]	[17]
Amisulpride	DMSJVAM	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Amisulpride.	Schizophrenia [6A20]	[18]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Asenapine.	Schizophrenia [6A20]	[17]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Pimozide.	Schizophrenia [6A20]	[17]

Coadministration of a Drug Treating the Disease Different from Olanzapine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[18]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Midostaurin.	Acute myeloid leukaemia [2A60]	[18]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Idarubicin.	Acute myeloid leukaemia [2A60]	[18]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[18]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Arn-509.	Acute myeloid leukaemia [2A60]	[18]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Oliceridine.	Acute pain [MG31]	[18]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[17]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[19]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[19]
Tacrine	DM51FY6	Moderate	Antagonize the effect of Olanzapine when combined with Tacrine.	Alzheimer disease [8A20]	[20]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Memantine.	Alzheimer disease [8A20]	[17]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Olanzapine when combined with Rivastigmine.	Alzheimer disease [8A20]	[20]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Olanzapine when combined with Donepezil.	Alzheimer disease [8A20]	[20]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Olanzapine and Metronidazole.	Amoebiasis [1A36]	[18]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Olanzapine and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[21]
Trimethaphan	DMHF4IQ	Moderate	Additive hypotensive effects by the combination of Olanzapine and Trimethaphan.	Aneurysm/dissection [BD50]	[22]
Bepridil	DM0RKS4	Moderate	Additive hypotensive effects by the combination of Olanzapine and Bepridil.	Angina pectoris [BA40]	[21]
Dronedarone	DMA8FS5	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Dronedarone.	Angina pectoris [BA40]	[18]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Olanzapine and Amyl nitrite.	Angina pectoris [BA40]	[21]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Olanzapine and Nifedipine.	Angina pectoris [BA40]	[21]
Bedaquiline	DM3906J	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[18]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[17]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Cilostazol.	Arterial occlusive disease [BD40]	[18]
Voriconazole	DMAOL2S	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Voriconazole.	Aspergillosis [1F20]	[18]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Posaconazole.	Aspergillosis [1F20]	[18]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Levalbuterol.	Asthma [CA23]	[18]
Terbutaline	DMD4381	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Terbutaline.	Asthma [CA23]	[18]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Pirbuterol.	Asthma [CA23]	[18]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Salbutamol.	Asthma [CA23]	[18]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[18]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[17]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Olanzapine caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[23]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased metabolism of Olanzapine caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[18]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Olanzapine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[24]
Sparfloxacin	DMB4HCT	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[18]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Retigabine.	Behcet disease [4A62]	[18]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Cariprazine.	Bipolar disorder [6A60]	[17]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Eribulin.	Breast cancer [2C60-2C6Y]	[18]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Lapatinib.	Breast cancer [2C60-2C6Y]	[18]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[18]
Toremifene	DMQYUWG	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Toremifene.	Breast cancer [2C60-2C6Y]	[18]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Bosutinib.	Breast cancer [2C60-2C6Y]	[18]
Sotalol	DML60TN	Moderate	Additive hypotensive effects by the combination of Olanzapine and Sotalol.	Cardiac arrhythmia [BC9Z]	[21]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Olanzapine when combined with Acetylcholine.	Cataract [9B10]	[25]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[18]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[26]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[26]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Olanzapine and Dihydrocodeine.	Chronic pain [MG30]	[27]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Oxaliplatin.	Colorectal cancer [2B91]	[18]
Isoproterenol	DMK7MEY	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Isoproterenol.	Conduction disorder [BC63]	[18]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Olanzapine and Olopatadine.	Conjunctiva disorder [9A60]	[28]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Halothane.	Corneal disease [9A76-9A78]	[18]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Propofol.	Corneal disease [9A76-9A78]	[29]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Sevoflurane.	Corneal disease [9A76-9A78]	[18]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Olanzapine and Alfentanil.	Corneal disease [9A76-9A78]	[30]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Olanzapine and Remifentanil.	Corneal disease [9A76-9A78]	[30]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Probucol.	Coronary atherosclerosis [BA80]	[18]
Nimodipine	DMQ0RKZ	Moderate	Additive hypotensive effects by the combination of Olanzapine and Nimodipine.	Coronary vasospastic disease [BA85]	[21]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Clofazimine.	Crohn disease [DD70]	[18]
Pasireotide	DMHM7JS	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Pasireotide.	Cushing syndrome [5A70]	[18]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Olanzapine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[23]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Olanzapine and Ethanol.	Cystitis [GC00]	[28]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Olanzapine and Cyclandelate.	Dementia [6D80-6D8Z]	[21]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[17]
Imipramine	DM2NUH3	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Imipramine.	Depression [6A70-6A7Z]	[17]
Nortriptyline	DM4KDYJ	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Nortriptyline.	Depression [6A70-6A7Z]	[17]
Escitalopram	DMFK9HG	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Escitalopram.	Depression [6A70-6A7Z]	[18]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Olanzapine and OPC-34712.	Depression [6A70-6A7Z]	[17]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Clomipramine.	Depression [6A70-6A7Z]	[17]
Trazodone	DMK1GBJ	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Trazodone.	Depression [6A70-6A7Z]	[18]
Amoxapine	DMKITQE	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Amoxapine.	Depression [6A70-6A7Z]	[17]
Protriptyline	DMNHTZI	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Protriptyline.	Depression [6A70-6A7Z]	[17]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Doxepin.	Depression [6A70-6A7Z]	[17]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Maprotiline.	Depression [6A70-6A7Z]	[17]
Nitroglycerin	DMQ2491	Moderate	Additive hypotensive effects by the combination of Olanzapine and Nitroglycerin.	Diabetic foot ulcer [BD54]	[21]
Hyoscyamine	DM804UR	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Hyoscyamine.	Digestive system disease [DE2Z]	[17]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Mepenzolate.	Digestive system disease [DE2Z]	[17]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Oxybutynine.	Discovery agent [N.A.]	[17]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Olanzapine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[31]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Meclizine.	Dizziness and giddiness [MB48]	[17]
Trihexyphenidyl	DMB19L8	Moderate	Antagonize the effect of Olanzapine when combined with Trihexyphenidyl.	Dystonic disorder [8A02]	[32]
Deutetrabenazine	DMUPFLI	Major	Additive antidopaminergic effects by the combination of Olanzapine and Deutetrabenazine.	Dystonic disorder [8A02]	[33]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Ingrezza.	Dystonic disorder [8A02]	[18]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Olanzapine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[34]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Olanzapine caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Diphenhydramine	DMKQTBA	Moderate	Antagonize the effect of Olanzapine when combined with Diphenhydramine.	Episodic vestibular syndrome [AB31]	[32]
Timolol	DM3NXRU	Moderate	Additive hypotensive effects by the combination of Olanzapine and Timolol.	Essential hypertension [BA00]	[21]
Guanabenz	DM5QWEL	Moderate	Additive hypotensive effects by the combination of Olanzapine and Guanabenz.	Essential hypertension [BA00]	[21]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Olanzapine and Ethacrynic acid.	Essential hypertension [BA00]	[22]
Bendroflumethiazide	DM7EVLC	Moderate	Additive hypotensive effects by the combination of Olanzapine and Bendroflumethiazide.	Essential hypertension [BA00]	[21]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Olanzapine and Phenoxybenzamine.	Essential hypertension [BA00]	[21]
Guanethidine	DM9NSWT	Moderate	Additive hypotensive effects by the combination of Olanzapine and Guanethidine.	Essential hypertension [BA00]	[21]
Nicardipine	DMCDYW7	Moderate	Additive hypotensive effects by the combination of Olanzapine and Nicardipine.	Essential hypertension [BA00]	[21]
Mecamylamine	DMGQFYB	Moderate	Additive hypotensive effects by the combination of Olanzapine and Mecamylamine.	Essential hypertension [BA00]	[21]
Benzthiazide	DMQWZ0H	Moderate	Additive hypotensive effects by the combination of Olanzapine and Benzthiazide.	Essential hypertension [BA00]	[21]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Olanzapine and Nadolol.	Essential hypertension [BA00]	[21]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Solifenacin.	Functional bladder disorder [GC50]	[17]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Tolterodine.	Functional bladder disorder [GC50]	[17]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Pentamidine.	Fungal infection [1F29-1F2F]	[18]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Olanzapine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Ketoconazole.	Fungal infection [1F29-1F2F]	[18]
Phentolamine	DMXYJOB	Moderate	Additive hypotensive effects by the combination of Olanzapine and Phentolamine.	Gangrene [MC85]	[21]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Propantheline.	Gastric ulcer [DA60]	[17]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[18]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Olanzapine when combined with Isoflurophate.	Glaucoma [9C61]	[25]
Carteolol	DMFMDOB	Moderate	Additive hypotensive effects by the combination of Olanzapine and Carteolol.	Glaucoma [9C61]	[21]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Olanzapine and Brimonidine.	Glaucoma [9C61]	[37]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Olanzapine when combined with Pilocarpine.	Glaucoma [9C61]	[25]
Spironolactone	DM2AQ5N	Moderate	Additive hypotensive effects by the combination of Olanzapine and Spironolactone.	Heart failure [BD10-BD1Z]	[21]
Triamterene	DM2HU9I	Moderate	Additive hypotensive effects by the combination of Olanzapine and Triamterene.	Heart failure [BD10-BD1Z]	[21]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Olanzapine and Prazosin.	Heart failure [BD10-BD1Z]	[21]
Eplerenone	DMF0NQR	Moderate	Additive hypotensive effects by the combination of Olanzapine and Eplerenone.	Heart failure [BD10-BD1Z]	[21]
Chlorothiazide	DMLHESP	Moderate	Additive hypotensive effects by the combination of Olanzapine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[21]
Furosemide	DMMQ8ZG	Moderate	Additive hypotensive effects by the combination of Olanzapine and Furosemide.	Heart failure [BD10-BD1Z]	[21]
Amiloride	DMRTSGP	Moderate	Additive hypotensive effects by the combination of Olanzapine and Amiloride.	Heart failure [BD10-BD1Z]	[21]
Bumetanide	DMRV7H0	Moderate	Additive hypotensive effects by the combination of Olanzapine and Bumetanide.	Heart failure [BD10-BD1Z]	[21]
Hydroflumethiazide	DMVPUQI	Moderate	Additive hypotensive effects by the combination of Olanzapine and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[21]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Efavirenz	DMC0GSJ	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Saquinavir	DMG814N	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Ritonavir	DMU764S	Moderate	Increased metabolism of Olanzapine caused by Ritonavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Olanzapine and Isosorbide mononitrate.	Hydrocephalus [8D64]	[21]
Teriflunomide	DMQ2FKJ	Moderate	Increased metabolism of Olanzapine caused by Teriflunomide mediated induction of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[35]
Eprosartan	DM07K2I	Moderate	Additive hypotensive effects by the combination of Olanzapine and Eprosartan.	Hypertension [BA00-BA04]	[21]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Olanzapine and Acebutolol.	Hypertension [BA00-BA04]	[21]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Olanzapine and Moexipril.	Hypertension [BA00-BA04]	[21]
Bisoprolol	DM3UZ95	Moderate	Additive hypotensive effects by the combination of Olanzapine and Bisoprolol.	Hypertension [BA00-BA04]	[21]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Olanzapine and Captopril.	Hypertension [BA00-BA04]	[21]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Olanzapine and Penbutolol.	Hypertension [BA00-BA04]	[21]
Trandolapril	DM4L6EU	Moderate	Additive hypotensive effects by the combination of Olanzapine and Trandolapril.	Hypertension [BA00-BA04]	[21]
Methyldopa	DM5I621	Moderate	Additive hypotensive effects by the combination of Olanzapine and Methyldopa.	Hypertension [BA00-BA04]	[21]
Clonidine	DM6RZ9Q	Moderate	Additive hypotensive effects by the combination of Olanzapine and Clonidine.	Hypertension [BA00-BA04]	[21]
Losartan	DM72JXH	Moderate	Additive hypotensive effects by the combination of Olanzapine and Losartan.	Hypertension [BA00-BA04]	[21]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Olanzapine and Nebivolol.	Hypertension [BA00-BA04]	[21]
Nisoldipine	DM7ISKJ	Moderate	Additive hypotensive effects by the combination of Olanzapine and Nisoldipine.	Hypertension [BA00-BA04]	[21]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Olanzapine and Levamlodipine.	Hypertension [BA00-BA04]	[21]
Fosinopril	DM9NJ52	Moderate	Additive hypotensive effects by the combination of Olanzapine and Fosinopril.	Hypertension [BA00-BA04]	[21]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Olanzapine and Doxazosin.	Hypertension [BA00-BA04]	[21]
Minoxidil	DMA2Z4F	Moderate	Additive hypotensive effects by the combination of Olanzapine and Minoxidil.	Hypertension [BA00-BA04]	[21]
Verapamil	DMA7PEW	Moderate	Additive hypotensive effects by the combination of Olanzapine and Verapamil.	Hypertension [BA00-BA04]	[21]
Diltiazem	DMAI7ZV	Moderate	Additive hypotensive effects by the combination of Olanzapine and Diltiazem.	Hypertension [BA00-BA04]	[21]
Amlodipine	DMBDAZV	Moderate	Additive hypotensive effects by the combination of Olanzapine and Amlodipine.	Hypertension [BA00-BA04]	[21]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Olanzapine and TAK-491.	Hypertension [BA00-BA04]	[21]
Pindolol	DMD2NV7	Moderate	Additive hypotensive effects by the combination of Olanzapine and Pindolol.	Hypertension [BA00-BA04]	[21]
Fenoldopam	DMFAOKP	Moderate	Additive hypotensive effects by the combination of Olanzapine and Fenoldopam.	Hypertension [BA00-BA04]	[21]
Indapamide	DMGN1PW	Moderate	Additive hypotensive effects by the combination of Olanzapine and Indapamide.	Hypertension [BA00-BA04]	[21]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Olanzapine and Trichlormethiazide.	Hypertension [BA00-BA04]	[21]
Labetalol	DMK8U72	Moderate	Additive hypotensive effects by the combination of Olanzapine and Labetalol.	Hypertension [BA00-BA04]	[21]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Olanzapine and Diazoxide.	Hypertension [BA00-BA04]	[21]
Enalapril	DMNFUZR	Moderate	Additive hypotensive effects by the combination of Olanzapine and Enalapril.	Hypertension [BA00-BA04]	[21]
Atenolol	DMNKG1Z	Moderate	Additive hypotensive effects by the combination of Olanzapine and Atenolol.	Hypertension [BA00-BA04]	[21]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Olanzapine and Perindopril.	Hypertension [BA00-BA04]	[21]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Olanzapine and Felodipine.	Hypertension [BA00-BA04]	[21]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Olanzapine and Quinapril.	Hypertension [BA00-BA04]	[21]
Deserpidine	DMRH7CV	Moderate	Additive hypotensive effects by the combination of Olanzapine and Deserpidine.	Hypertension [BA00-BA04]	[21]
Telmisartan	DMS3GX2	Moderate	Additive hypotensive effects by the combination of Olanzapine and Telmisartan.	Hypertension [BA00-BA04]	[21]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Olanzapine and Irbesartan.	Hypertension [BA00-BA04]	[21]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Olanzapine and Hydralazine.	Hypertension [BA00-BA04]	[21]
Hydrochlorothiazide	DMUSZHD	Moderate	Additive hypotensive effects by the combination of Olanzapine and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[21]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Olanzapine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[21]
Potassium chloride	DMMTAJC	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Olanzapine and Potassium chloride.	Hypo-kalaemia [5C77]	[39]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Olanzapine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[23]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Amantadine.	Influenza [1E30-1E32]	[40]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Propiomazine.	Insomnia [7A00-7A0Z]	[17]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Olanzapine and ITI-007.	Insomnia [7A00-7A0Z]	[17]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Olanzapine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[41]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Clidinium.	Irritable bowel syndrome [DD91]	[17]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Olanzapine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[20]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Olanzapine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[35]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Olanzapine and Porfimer Sodium.	Lung cancer [2C25]	[42]
Ceritinib	DMB920Z	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Ceritinib.	Lung cancer [2C25]	[18]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Olanzapine caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[43]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Olanzapine caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[23]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Olanzapine caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[18]
Halofantrine	DMOMK1V	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Halofantrine.	Malaria [1F40-1F45]	[18]
Chloroquine	DMSI5CB	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Chloroquine.	Malaria [1F40-1F45]	[18]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Hydroxychloroquine.	Malaria [1F40-1F45]	[18]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Quinine.	Malaria [1F40-1F45]	[18]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Primaquine.	Malaria [1F40-1F45]	[18]
Mefloquine	DMWT905	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Mefloquine.	Malaria [1F40-1F45]	[18]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[18]
Arsenic trioxide	DM61TA4	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[18]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Olanzapine caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[23]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and LGX818.	Melanoma [2C30]	[18]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Olanzapine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[44]
Propranolol	DM79NTF	Moderate	Additive hypotensive effects by the combination of Olanzapine and Propranolol.	Migraine [8A80]	[21]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Olanzapine and Lasmiditan.	Migraine [8A80]	[45]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Olanzapine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[23]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Olanzapine and Flibanserin.	Mood disorder [6A60-6E23]	[46]
Doxylamine	DMKOXFE	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Doxylamine.	Morning sickness disorder [SC00]	[17]
Panobinostat	DM58WKG	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Panobinostat.	Multiple myeloma [2A83]	[18]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Olanzapine and Thalidomide.	Multiple myeloma [2A83]	[47]
Siponimod	DM2R86O	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Siponimod.	Multiple sclerosis [8A40]	[18]
Fingolimod	DM5JVAN	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Fingolimod.	Multiple sclerosis [8A40]	[18]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Olanzapine and Ozanimod.	Multiple sclerosis [8A40]	[18]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Romidepsin.	Mycosis fungoides [2B01]	[18]
Nilotinib	DM7HXWT	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[18]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Olanzapine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[48]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[18]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Phenindamine.	Nasopharyngitis [CA00]	[17]
Droperidol	DM0DXA8	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Droperidol.	Nausea/vomiting [MD90]	[18]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Dimenhydrinate.	Nausea/vomiting [MD90]	[17]
Prochlorperazine	DM53SRA	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Prochlorperazine.	Nausea/vomiting [MD90]	[17]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Promethazine.	Nausea/vomiting [MD90]	[17]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Cyclizine.	Nausea/vomiting [MD90]	[17]
Palonosetron	DMBHMOX	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Palonosetron.	Nausea/vomiting [MD90]	[18]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Olanzapine and Metoclopramide.	Nausea/vomiting [MD90]	[49]
Dolasetron	DMMG26Z	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Dolasetron.	Nausea/vomiting [MD90]	[18]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Ondansetron.	Nausea/vomiting [MD90]	[18]
Thiethylperazine	DMU3IET	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Thiethylperazine.	Nausea/vomiting [MD90]	[17]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Olanzapine and Bupropion.	Nicotine use disorder [6C4A]	[50]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Olanzapine caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[51]
Metolazone	DMB39LO	Moderate	Additive hypotensive effects by the combination of Olanzapine and Metolazone.	Oedema [MG29]	[21]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Olanzapine and Polythiazide.	Oedema [MG29]	[21]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Olanzapine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[27]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Olanzapine and Lofexidine.	Opioid use disorder [6C43]	[21]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Olanzapine and Apraclonidine.	Optic nerve disorder [9C40]	[37]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Olanzapine caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[18]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Olanzapine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[23]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Olanzapine and Pentazocine.	Pain [MG30-MG3Z]	[30]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Olanzapine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[52]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Olanzapine and Butorphanol.	Pain [MG30-MG3Z]	[30]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Olanzapine and Oxymorphone.	Pain [MG30-MG3Z]	[30]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Olanzapine and Levorphanol.	Pain [MG30-MG3Z]	[30]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Olanzapine and Dezocine.	Pain [MG30-MG3Z]	[30]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Flavoxate.	Pain [MG30-MG3Z]	[17]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Olanzapine and Nalbuphine.	Pain [MG30-MG3Z]	[30]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Olanzapine and Buprenorphine.	Pain [MG30-MG3Z]	[53]
Meperidine	DMX4GND	Major	Additive CNS depression effects by the combination of Olanzapine and Meperidine.	Pain [MG30-MG3Z]	[30]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Olanzapine and Oxycodone.	Pain [MG30-MG3Z]	[30]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Triclabendazole.	Parasitic worm infestation [1F90]	[18]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Olanzapine when combined with Pergolide.	Parkinsonism [8A00]	[54]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Olanzapine when combined with Opicapone.	Parkinsonism [8A00]	[54]
Biperiden	DME78OA	Moderate	Antagonize the effect of Olanzapine when combined with Biperiden.	Parkinsonism [8A00]	[32]
Procyclidine	DMHFJDT	Moderate	Antagonize the effect of Olanzapine when combined with Procyclidine.	Parkinsonism [8A00]	[32]
Entacapone	DMLBVKQ	Moderate	Antagonize the effect of Olanzapine when combined with Entacapone.	Parkinsonism [8A00]	[54]
Levodopa	DMN3E57	Moderate	Antagonize the effect of Olanzapine when combined with Levodopa.	Parkinsonism [8A00]	[54]
Pramipexole	DMNMW9R	Moderate	Additive hypotensive effects by the combination of Olanzapine and Pramipexole.	Parkinsonism [8A00]	[54]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Pimavanserin.	Parkinsonism [8A00]	[18]
Bromocriptine	DMVE3TK	Moderate	Antagonize the effect of Olanzapine when combined with Bromocriptine.	Parkinsonism [8A00]	[54]
Apomorphine	DMX38HQ	Moderate	Antagonize the effect of Olanzapine when combined with Apomorphine.	Parkinsonism [8A00]	[55]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Olanzapine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[56]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Olanzapine and Lindane.	Pediculosis [1G00]	[57]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Methylscopolamine.	Peptic ulcer [DA61]	[17]
Macimorelin	DMQYJIR	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[18]
Lefamulin	DME6G97	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Lefamulin.	Pneumonia [CA40]	[18]
Ritodrine	DM4V6RL	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Ritodrine.	Preterm labour/delivery [JB00]	[18]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Degarelix.	Prostate cancer [2C82]	[18]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and ABIRATERONE.	Prostate cancer [2C82]	[18]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Nilutamide.	Prostate cancer [2C82]	[18]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Enzalutamide.	Prostate cancer [2C82]	[18]
Flutamide	DMK0O7U	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Flutamide.	Prostate cancer [2C82]	[18]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Relugolix.	Prostate cancer [2C82]	[18]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Bicalutamide.	Prostate cancer [2C82]	[18]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Olanzapine and Terazosin.	Prostate hyperplasia [GA90]	[21]
Alfuzosin	DMZVMKF	Moderate	Additive hypotensive effects by the combination of Olanzapine and Alfuzosin.	Prostate hyperplasia [GA90]	[21]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[17]
Triflupromazine	DMKFQJP	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[17]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Olanzapine and Tolazoline.	Pulmonary hypertension [BB01]	[21]
Sorafenib	DMS8IFC	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Sorafenib.	Renal cell carcinoma [2C90]	[18]
Gatifloxacin	DMSL679	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[18]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Olanzapine when combined with Neupro.	Restless legs syndrome [7A80]	[54]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Olanzapine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[58]
Cyproheptadine	DM92AH3	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Cyproheptadine.	Rheumatoid arthritis [FA20]	[17]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Olanzapine and Fentanyl.	Sensation disturbance [MB40]	[30]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Olanzapine and Sufentanil.	Sensation disturbance [MB40]	[30]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[18]
Epirubicin	DMPDW6T	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[18]
Vandetanib	DMRICNP	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[18]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[18]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[18]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Pitolisant.	Somnolence [MG42]	[18]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[18]
Cabozantinib	DMIYDT4	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Cabozantinib.	Thyroid cancer [2D10]	[18]
Papaverine	DMCA9QP	Moderate	Additive hypotensive effects by the combination of Olanzapine and Papaverine.	Tonus and reflex abnormality [MB47]	[21]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Olanzapine and Tizanidine.	Tonus and reflex abnormality [MB47]	[59]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Atropine.	Unspecific substance harmful effect [NE6Z]	[17]
Enoxacin	DMYTE6L	Minor	Decreased metabolism of Olanzapine caused by Enoxacin mediated inhibition of CYP450 enzyme.	Urinary tract infection [GC08]	[23]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[18]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[17]
Triprolidine	DM7SWIA	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Triprolidine.	Vasomotor/allergic rhinitis [CA08]	[17]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[17]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[17]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[19]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[17]
Dexbrompheniramine	DMKVWGE	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Dexbrompheniramine.	Vasomotor/allergic rhinitis [CA08]	[17]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Olanzapine and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[60]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[17]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Olanzapine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[17]
Procainamide	DMNMXR8	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[18]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[18]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[18]
Amiodarone	DMUTEX3	Moderate	Increased risk of prolong QT interval by the combination of Olanzapine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[18]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Aspartame	E00402	134601	Flavoring agent
Benzyl alcohol	E00010	244	Antimicrobial preservative; Solvent
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Propylparaben sodium	E00567	23679044	Antimicrobial preservative
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium methylparaben	E00543	23663626	Antimicrobial preservative
Sodium stearyl fumarate	E00545	23665634	lubricant
Sucralose	E00370	71485	Flavoring agent
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Magnesium sulfate	E00281	24083	Vaccine adjuvant
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Xylitol	E00136	6912	Coating agent; Diluent; Emollient; Flavoring agent; Humectant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Olanzapine 10 mg tablet	10 mg	Disintegrating Oral Tablet	Oral
Olanzapine 15 mg tablet	15 mg	Disintegrating Oral Tablet	Oral
Olanzapine 20 mg tablet	20 mg	Disintegrating Oral Tablet	Oral
Olanzapine 5 mg tablet	5 mg	Disintegrating Oral Tablet	Oral
Olanzapine 20 mg tablet	20 mg	Oral Tablet	Oral
Olanzapine 15 mg tablet	15 mg	Oral Tablet	Oral
Olanzapine 10 mg tablet	10 mg	Disintegrating Tablet	Oral
Olanzapine 15 mg tablet	15 mg	Disintegrating Tablet	Oral
Olanzapine 20 mg tablet	20 mg	Disintegrating Tablet	Oral
Olanzapine 5 mg tablet	5 mg	Disintegrating Tablet	Oral
Olanzapine 10 mg tablet	10 mg	Oral Tablet	Oral
Olanzapine 2.5 mg tablet	2.5 mg	Oral Tablet	Oral
Olanzapine 5 mg tablet	5 mg	Oral Tablet	Oral
Olanzapine 7.5 mg tablet	7.5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Olanzapine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 47).
• [3] Olanzapine .
• [4] BDDCS applied to over 900 drugs
• [5] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [8] Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-61.
• [9] Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
• [10] [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. Fortschr Neurol Psychiatr. 2001 Nov;69(11):510-7.
• [11] Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003 Mar;28(2):99-112.
• [12] Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci. 2006 Oct 20;7:69.
• [13] Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia. Adv Ther. 2010 May;27(5):307-13. doi: 10.1007/s12325-010-0035-4. Epub 2010 Jun 8.
• [14] No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
• [15] Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J. 2009 Aug;9(4):234-41. doi: 10.1038/tpj.2009.18. Epub 2009 May 12.
• [16] Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia. Proteomics Clin Appl. 2015 Oct;9(9-10):907-16. doi: 10.1002/prca.201400148. Epub 2015 May 15.
• [17] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [18] Cerner Multum, Inc. "Australian Product Information.".
• [19] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [20] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [21] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [22] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [23] Albers LJ, Ozdemir V, Marder SR, et al. "Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy." J Clin Psychopharmacol 25 (2005): 170-174. [PMID: 15738749]
• [24] Canadian Pharmacists Association.
• [25] Multum Information Services, Inc. Expert Review Panel.
• [26] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [27] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [28] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [29] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [30] Cerner Multum, Inc. "Canadian Product Information.".
• [31] Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
• [32] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
• [33] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [34] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [35] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [36] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [37] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [38] Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW "Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers." J Clin Psychopharmacol 22 (2002): 366-370. [PMID: 12172335]
• [39] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
• [40] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [41] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [42] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [43] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [44] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [45] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [46] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [47] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [48] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [49] Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
• [50] Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
• [51] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [52] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
• [53] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
• [54] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [55] Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
• [56] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [57] Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
• [58] Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
• [59] Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
• [60] Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.